Suppr超能文献

靶向HIV-1 gp120 V3环的生物活性单链可变抗体片段的制备。

Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop.

作者信息

Ong Y T, Kirby K A, Hachiya A, Chiang L A, Marchand B, Yoshimura K, Murakami T, Singh K, Matsushita S, Sarafianos S G

机构信息

Christopher S. Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, MO 65211, USA.

出版信息

Cell Mol Biol (Noisy-le-grand). 2012 Dec 22;58(1):71-9.

Abstract

KD-247 is a humanized monoclonal antibody that targets the third hypervariable (V3) loop of gp120. It can efficiently neutralize a broad panel of clade B, but not non-clade B, HIV-1 isolates. To overcome this limitation, we are seeking to prepare genetically-engineered single-chain variable fragments (scFvs) of KD-247 that will have broader neutralizing activity against both clade B and non-clade B HIV-1 isolates. Initial attempts of optimizing the expression of KD-247 scFv have resulted in the formation of insoluble protein. Therefore, we have established purification protocols to recover, purify, and refold the KD-247 scFv from inclusion bodies. The protocol involved step-wise refolding of denatured scFv by dilution, dialysis, and on-column nickel-affinity purification. Monomeric scFv was further purified by size-exclusion chromatography. Using far UV circular dichroism (CD) spectroscopy we confirmed the expected beta-sheet profile of the refolded KD-247 scFv. Importantly, the refolded KD-247 scFv showed neutralizing activity against replication-competent HIV-1 BaL and JR-FL Env pseudotyped HIV-1, at potency comparable to that of the native full-size KD-247 antibody. Ongoing studies focus on the application of this system in generating KD-247 scFv variants with the ability to neutralize clade B and non-clade B HIV-1 isolates.

摘要

KD - 247是一种靶向gp120第三高变区(V3环)的人源化单克隆抗体。它能有效中和多种B亚型HIV - 1分离株,但对非B亚型HIV - 1分离株无效。为克服这一局限性,我们正致力于制备KD - 247的基因工程单链可变片段(scFv),使其对B亚型和非B亚型HIV - 1分离株均具有更广泛的中和活性。最初优化KD - 247 scFv表达的尝试导致了不溶性蛋白的形成。因此,我们建立了从包涵体中回收、纯化和重折叠KD - 247 scFv的纯化方案。该方案包括通过稀释、透析和柱上镍亲和纯化对变性的scFv进行逐步重折叠。单体scFv通过尺寸排阻色谱进一步纯化。使用远紫外圆二色性(CD)光谱,我们确认了重折叠的KD - 247 scFv具有预期的β - 折叠结构。重要的是,重折叠的KD - 247 scFv对有复制能力的HIV - 1 BaL和JR - FL Env假型化HIV - 1显示出中和活性,其效力与天然全长KD - 247抗体相当。正在进行的研究聚焦于该系统在生成具有中和B亚型和非B亚型HIV - 1分离株能力的KD - 247 scFv变体中的应用。

相似文献

3
Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.
FASEB J. 2015 Jan;29(1):70-80. doi: 10.1096/fj.14-252262. Epub 2014 Oct 28.
5
7
Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.
J Virol. 2014 Nov;88(21):12853-65. doi: 10.1128/JVI.02125-14. Epub 2014 Aug 27.
9
HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.
10
A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C.
BMC Biotechnol. 2012 Nov 15;12:87. doi: 10.1186/1472-6750-12-87.

本文引用的文献

1
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278.
2
Neutralizing antibodies and control of HIV: moves and countermoves.
Curr HIV/AIDS Rep. 2012 Mar;9(1):64-72. doi: 10.1007/s11904-011-0105-5.
3
Antibody-based protection against HIV infection by vectored immunoprophylaxis.
Nature. 2011 Nov 30;481(7379):81-4. doi: 10.1038/nature10660.
4
Single-chain Fv-based anti-HIV proteins: potential and limitations.
J Virol. 2012 Jan;86(1):195-202. doi: 10.1128/JVI.05848-11. Epub 2011 Oct 19.
5
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.
Nat Med. 2010 Oct;16(10):1117-9. doi: 10.1038/nm.2233. Epub 2010 Oct 3.
6
Alternative antibody formats.
Curr Opin Mol Ther. 2010 Apr;12(2):176-83.
7
Expression of single-chain Fv fragments in E. coli cytoplasm.
Methods Mol Biol. 2009;562:215-24. doi: 10.1007/978-1-60327-302-2_17.
8
High-level periplasmic expression and purification of scFvs.
Methods Mol Biol. 2009;562:205-14. doi: 10.1007/978-1-60327-302-2_16.
9
Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.
Curr Opin HIV AIDS. 2009 Mar;4(2):112-7. doi: 10.1097/COH.0b013e328322f95e.
10
Affinity maturation by phage display.
Methods Mol Biol. 2009;525:309-22, xv. doi: 10.1007/978-1-59745-554-1_16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验